| Document |
Document Title |
|
WO/2022/133114A1 |
Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, L and J are as defined in...
|
|
WO/2022/132803A1 |
Provided herein are compounds, compositions, and methods for treating disorders (e.g., opioid addiction) using compounds disclosed herein, which are selective agonists of the cannabinoid 2 receptor (CB2R).
|
|
WO/2022/129188A1 |
The present invention relates to 1,2,4-oxadiazol-3-ylpyrimidine compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection (formula (I)).
|
|
WO/2022/129190A1 |
The present invention relates to the use of (hetero)aryl substituted 1,2,4-oxadiazole compounds for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection (formula (I)). It also relates to novel (hete...
|
|
WO/2022/127904A1 |
Provided are a pharmaceutically acceptable salt of an indazole derivative, and a crystalline form and a preparation method therefor. Particularly, provided are a crystal form of a pharmaceutically acceptable salt of a compound represente...
|
|
WO/2022/132679A1 |
The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to com...
|
|
WO/2022/129125A1 |
The present invention related to compounds of Formula (I):(I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to...
|
|
WO/2022/131741A1 |
The present invention relates to an isoxazolidine derivative compound and the use thereof. The isoxazolidine derivative compound of the present invention exhibits excellent inhibitory activity against CDK2, CDK4, CDK6 and/or HPK1, and th...
|
|
WO/2022/123039A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as "ALDHI compounds"), that, ...
|
|
WO/2022/122882A1 |
The invention relates to a process for producing a benzoxazine containing free aliphatic hydroxyl groups and monoester comprising the steps of: a) a reaction of a phenolic acid derivative with a monofunctional oligomer or molecule at a t...
|
|
WO/2022/123314A1 |
Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
|
|
WO/2022/125610A1 |
Disclosed are compositions and methods related to the formulation and administration of vaccines to an individual in need thereof. In one aspect, the disclosed compositions and methods relate to improving the ability of a vaccine to prev...
|
|
WO/2022/122735A1 |
The invention also relates to a process for synthesizing an ester-containing benzoxazine monomer comprising the steps of a) reacting a phenolic acid derivative with a polyfunctional molecule or oligomer at a temperature of from 25°C to ...
|
|
WO/2022/123502A1 |
The present invention discloses an isoxazoline compounds of formula (I), Formula (I) 5 wherein, R1, R2, R4, R5, R6, A, W and n are as defined in the detailed description. The present invention further discloses methods for preparation of...
|
|
WO/2022/121805A1 |
The present invention provides a fused ring compound as a sodium channel blocker and a use thereof. The fused ring compound has inhibitory activity on a sodium ion channel Nav1.8, and can be used as a drug for extensive pain treatment.
|
|
WO/2022/125849A1 |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).
|
|
WO/2022/122037A1 |
Provided are a dihydroisoquinolinone derivative and an application thereof. The dihydroisoquinolinone derivative is represented by formula I, and comprises a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a t...
|
|
WO/2022/122035A1 |
Provided are a coagulation factor XIa inhibitor, a preparation method, a pharmaceutical composition and the use thereof for preventing or treating diseases related to the activity of FXIa. Specifically, provided are an amide derivative a...
|
|
WO/2022/121868A1 |
A TYK2 inhibitor compound containing an amide group and a heterocycloalkyl group and a preparation method therefor, and the present invention relates to a use thereof in the preparation of a drug for treating or preventing TYK2-related d...
|
|
WO/2022/118910A1 |
[Problem] The purpose of the present invention is to provide a compound that has a high refractive index with respect to the wavelength range of 450-750 nm in a capping layer, in order to improve the light extraction efficiency of an org...
|
|
WO/2022/087422A9 |
The present disclosure relates to compounds of Formula (I'): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are use...
|
|
WO/2022/120353A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/119362A1 |
The present invention relates to a GPX4 protein degradation-inducing compound. Specifically, the present invention provides: a bifunctional compound in which a GPX4 protein-binding moiety and a CRBN E3 ubiquitin ligase-binding moiety are...
|
|
WO/2022/120354A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/117920A1 |
The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclyl or a 4-12 membered heterocyclyl containing 1-4 heteroatoms selected from O, N or S; B is any of the following groups (1) (2) or (3 ); C is...
|
|
WO/2022/117445A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2022/119174A1 |
Provided is a dibenzo 5-membered cyclic compound that contributes to substantial improvements in the light efficiency and viewing angle of an organic electroluminescence device. The organic electroluminescence device according to the pre...
|
|
WO/2022/112207A1 |
The present invention provides novel compounds having the general formula wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/112072A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2022/112345A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112140A1 |
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...
|
|
WO/2022/112352A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112490A1 |
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositio...
|
|
WO/2022/114164A1 |
Provided is a compound which is useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody ...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/114189A1 |
Provided is a compound that exerts an anticancer effect based on the inhibition of CHK1. The present disclosure has been completed based on the finding that a compound represented by formula (1) or a pharmaceutically acceptable salt ther...
|
|
WO/2022/112205A1 |
The present invention provides novel compounds having the general formula (I) wherein A1 to A4, X1, X2 and R1 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/115879A1 |
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.
|
|
WO/2022/112139A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/111513A1 |
Provided are an aromatic compound represented by formula A or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof. The aromatic compound has a good inhibitory effect on KRAS, especially KRAS ...
|
|
WO/2022/107724A1 |
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...
|
|
WO/2022/106680A1 |
The present invention provides novel compounds having the general formula: (Formula I) wherein A1 to A4, X, Cy and R1 are as described herein, compositions including the compounds and methods of using the compounds as HBsAg inhibitors fo...
|
|
WO/2022/105771A1 |
The present invention relates to a nitrogen-containing heterocyclic derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a nitrogen-containing heterocyclic deriva...
|
|
WO/2022/107144A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with binding of IGF2BP1 to an RNA in a subject in need thereof ...
|
|
WO/2022/105908A1 |
The present invention relates to an EGFR inhibitor having a structure of formula (I) and a preparation method therefor, a pharmaceutical composition containing the EGFR inhibitor, a use of the pharmaceutical composition as the EGFR inhib...
|
|
WO/2022/106375A1 |
The present invention provides novel compounds having the general formula (I) wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/106589A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/101265A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/103899A1 |
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
|
|
WO/2022/100099A1 |
An organic compound, a mixture, a composition and an organic electroluminescence device. The organic compound has a high extinction coefficient in the ultraviolet region; has a high refractive index in the visible light region; can be us...
|
